There are now two FDA-approved GLP-1 pills for weight loss, and they are not the same drug. Dr. Clete Barrick (board-certified in internal medicine and obesity medicine) breaks down the side-by-side: the chemistry, the dosing rules, the weight loss data, the side effects, the cost, and which patient profile fits each pill.

What you'll learn:
- Why Foundayo (orforglipron) and oral Wegovy (semaglutide 25 mg) are pharmacologically different drugs, not just two brands of the same thing
- The morning ritual oral Wegovy requires and why pharmacokinetic studies say you can't cheat it
- Trial weight loss numbers from ATTAIN-1 (Foundayo) and OASIS 4 (oral Wegovy) and what the 1.2-point gap actually means in real life
- The side effect paradox: lower nausea on Foundayo but higher discontinuation at the top dose
- May 2026 self-pay and insured pricing through LillyDirect and NovoCare
- The patient profiles where each pill is the right answer, and the case where a needle is still better than a pill

Timestamps:
0:00 — Opening
0:45 — Welcome to Straight Shot
1:00 — Why this matters now
2:30 — Shot 1: The chemistry
4:45 — Shot 2: How you take each pill
7:00 — Shot 3: How much weight comes off
9:15 — Shot 4: The side effect paradox
11:30 — GLP-1 Bible pre-order
12:00 — Shot 5: What you'll actually pay
13:00 — The Straight Shot
14:30 — Wrap & subscribe

Studies and sources referenced:
- Wharton S, Aronne LJ, Stefanski A, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1). NEJM. 2025;393(18):1796-1806.
- Wharton S, Lingvay I, Bogdanski P, et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity (OASIS 4). NEJM. 2025;393(11):1077-1087.
- Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). NEJM. 2021;384(11):989-1002.
- Buckley ST et al. Transcellular stomach absorption of a derivatized GLP-1 receptor agonist. Sci Transl Med. 2018;10(467):eaar7047.
- Granhall C et al. Safety and pharmacokinetics of single and multiple ascending doses of oral semaglutide. Clin Pharmacokinet. 2019;58(6):781-791.
- Foundayo (orforglipron) Prescribing Information. Eli Lilly. April 2026.
- Wegovy (semaglutide tablets) Prescribing Information. Novo Nordisk. December 2025.
- Eli Lilly. ATTAIN-MAINTAIN press release, December 18, 2025.
- LillyDirect Foundayo pricing, April 2026.
- NovoCare Wegovy pricing, April 2026.

Resources:
- Pre-order The GLP-1 Bible: barrickhealth.com
- Book a 1-on-1 consult with Dr. Barrick: barrickhealth.com
- YouTube: @BarrickHealth
- Reddit: u/CleteBarrickMD

Disclaimer: This episode is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting, stopping, or changing any medication.